23AndMe To Go Public At $3.5Bn With Sir Richard Branson-Backed SPAC
23andMe is teaming up with blank check company VG Acquisition Corp to go public, making the move into personalized health care.
You may also be interested in...
With the acquisition of Lemonaid Health, at-home genome testing company 23andMe hopes to transform the primary care business with genetics insights.
According to Rock Health, 52 health-care focused SPACs are looking for targets. This comes as blank check companies are facing rising scrutiny by regulators.
Adaptive chief medical officer Lance Baldo talked to Medtech Insight about the company's plans to detect prior infection using T-cells obtained from blood samples.